Retroperitoneal lymph node dissection (RPLND) is a therapeutic standard of care for post-chemotherapy residual masses in testicular cancer. While a robotic approach to this procedure has the potential of decreasing the morbidity associated with this major endeavour, it is often criticised for its inability to provide a bilateral complete template resection without redocking and repositioning the patient. Herein, we present the technique and initial outcomes of a supine approach to Robotic RPLND (R-RPLND) using the da Vinci Xi® system, which obviates the need for repositioning or redocking for a bilateral full template resection. Three patients (age 21–36) with nonseminomatous germ cell tumours of the testis underwent R-RPLND for post-chemotherapy residual retroperitoneal masses with normalised tumor markers. Salient steps of the procedure were as follows: port placement in supine Trendelenburg position, docking of the da Vinci Xi® system from one side, exposure of retroperitoneum, dissection of paracaval, retrocaval, interaortocaval, paraaortic and bilateral common iliac templates, and excision of gonadal vein. Mean console time and estimated blood loss were 257 (190–305) minutes and 333 (300–400) ml, respectively. Mean lymph node yield was 52 (29–94). One patient had a common iliac vein injury which was managed robotically without further consequence. No drains were placed in all three. There were no postoperative complications and all of them were advanced to a normal diet within 24 h and discharged on the second postoperative day. Histopathology reports were suggestive of necrosis and mature teratoma without any viable tumour. There have been no recurrences in these patients at a mean follow-up of 14 (1–22) months. R-RPLND in the supine position is practical, safe and feasible in the post-chemotherapy setting of testicular cancer. It eliminates the need for repositioning the patient or redocking the robot to achieve a complete resection with adequate lymph node yields, while preserving the benefits of a minimally invasive surgical approach.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Gilligan T, Beard C, Carnerio B, Chism D, Cost N, Derweesh I et al Testicular cancer, version 2.2018, NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. Accessed 30 May 2018
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European germ cell cancer consensus group (EGCCCG): Part II. Eur Urol 53(3):497–513
Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP (2003) Is postchemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169(6):2126–2128
Stepanian S, Patel M, Porter J (2016) Robot-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer: evolution of the technique. Eur Urol 70(4):661–667
Donohue JP (1977) Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am 4(3):509–521
Cheney SM, Andrews PE, Leibovich BC, Castle EP (2015) Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int 115(1):114–120
EAU Guidelines Edn. Presented at EAU Annual Congress Copenhagen (2018) ISBN 978-94-92671-01-1. http://uroweb.org/guideline/testicular-cancer/#12. Accessed 30 May 2018
Kamel MH, Littlejohn N, Cox M, Eltahawy EA, Davis R (2016) Post-chemotherapy robotic retroperitoneal lymph node dissection: institutional experience. J Endourol 30(5):510–519
Singh A, Chatterjee S, Bansal P, Bansal A, Rawal S (2017) Robot-assisted retroperitoneal lymph node dissection: feasibility and outcome in post chemotherapy residual mass in testicular cancer. Indian J Urol 33(4):304–309
Pooleri GK, Bijalwan P, Kesavan R, Philip A, Keechilat P (2018) Robot-assisted supine extraperitoneal retroperitoneal lymph node dissection: a novel approach for template dissection in post-chemotherapy residual mass in non-seminomatous germ cell tumours. J Robot Surg. https://doi.org/10.1007/s11701-018-0810-9(Epub ahead of print)
Lee SH, Kim DS, Chang SG, Jeon SH (2015) Robot-assisted laparoscopic retroperitoneal lymph node dissection for stage IIIb mixed germ cell testicular cancer after chemotherapy. Korean J Urol 56(7):540–544
Overs C, Beauval JB, Mourey L, Rischmann P, Soulié M, Roumiguié M et al (2018) Robot-assisted post-chemotherapy retroperitoneal lymph nodedissection in germ cell tumor: is the single-docking with lateral approach relevant? World J Urol 36(4):655–661
Bora GS, Panwar P, Mavuduru RS, Devana SK, Singh SK, Mandal AK (2017) Post chemotherapy retroperitoneal lymph node dissection in germ cell tumor: robotic way. J Robot Surg 11(2):279–285
Stout TE, Soni SD, Goh AC (2016) Post-chemotherapy robotic bilateral retroperitoneal lymph node dissection using a novel single-dock technique. J Robot Surg 10(4):353–356
Rukstalis DB, Chodak GW (1992) Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol 148(6):1907–1909
Davol P, Sumfest J, Rukstalis D (2006) Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 67(1):199
Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP (2004) Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171(5):1839–1841
Janetschek G, Hobisch A, Hittmair A, Höltl L, Peschel R, Bartsch G (1999) Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIBnonseminomatous testicular carcinoma. J Urol 161(2):477–481
Permpongkosol S, Lima GC, Warlick CA, Allaf ME, Varkarakis IM, Bagga HS et a (2007) Post chemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology 69(2):361–365
Palese MA, Su LM, Kavoussi LR (2002) Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 60(1):130–134
Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D et al (2010) The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology 75(6):1431–1435
Murilo A, Luz AF, Kotb S, Aldousari et al (2010) Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol 8:97
Foster RS, Beck S, Bihrle R (2004) Secondary surgery in germ cell tumors—when and how extensively should it be performed? World J Urol 22(1):37–40
Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ et al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of modified post chemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25(28):4365–4369
Ehrlich Y, Yossepowitch O, Kedar D, Baniel J (2006) Distribution of nodal metastases after chemotherapy in non seminomatous testis cancer: a possible indication for limited dissection. BJU Int 97(6):1221–1224
Conflict of interest
Author Ashwin Sunil Tamhankar, Author Saurabh Patil, Author Surya Prakash Ojha, Author Puneet Ahluwalia and Author Gagan Gautam declare that they have no conflict of interest.
Informed consent was obtained from all patients for being included in the study.
About this article
Cite this article
Tamhankar, A.S., Patil, S.R., Ojha, S.P. et al. Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience. J Robotic Surg 13, 747–756 (2019). https://doi.org/10.1007/s11701-018-00903-0
- Retroperitoneal lymph node dissection
- Da Vinci Xi® system
- Post-chemotherapy residual masses in testicular cancer
- Robotic RPLND